Geron Co. (NASDAQ:GERN - Get Free Report) shares reached a new 52-week high during trading on Thursday . The stock traded as high as $3.77 and last traded at $3.73, with a volume of 12337390 shares trading hands. The stock had previously closed at $3.44.
Analyst Ratings Changes
GERN has been the topic of a number of research reports. Wedbush restated an "outperform" rating and issued a $6.00 price target on shares of Geron in a report on Wednesday. Needham & Company LLC restated a "buy" rating and set a $5.00 price objective on shares of Geron in a report on Thursday. Finally, The Goldman Sachs Group increased their price objective on shares of Geron from $4.00 to $5.00 and gave the stock a "buy" rating in a research report on Friday, March 15th.
Read Our Latest Stock Analysis on GERN
Geron Price Performance
The business's 50 day moving average price is $2.53 and its 200-day moving average price is $2.17. The company has a quick ratio of 3.16, a current ratio of 3.16 and a debt-to-equity ratio of 0.14. The company has a market cap of $2.06 billion, a PE ratio of -11.42 and a beta of 0.62.
Geron (NASDAQ:GERN - Get Free Report) last issued its quarterly earnings data on Wednesday, February 28th. The biopharmaceutical company reported ($0.09) EPS for the quarter, topping analysts' consensus estimates of ($0.10) by $0.01. Geron had a negative net margin of 77,691.14% and a negative return on equity of 63.33%. The firm had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.06 million. During the same quarter in the previous year, the business posted ($0.10) EPS. The firm's revenue was down 77.7% compared to the same quarter last year. As a group, analysts forecast that Geron Co. will post -0.34 earnings per share for the current year.
Hedge Funds Weigh In On Geron
A number of institutional investors have recently made changes to their positions in the business. PNC Financial Services Group Inc. bought a new stake in shares of Geron in the second quarter worth $32,000. Cerity Partners LLC bought a new stake in Geron in the fourth quarter valued at about $26,000. CIBC Asset Management Inc acquired a new stake in Geron during the fourth quarter valued at approximately $27,000. Pathstone Family Office LLC acquired a new stake in Geron during the third quarter valued at approximately $26,000. Finally, Creative Planning bought a new position in Geron during the 3rd quarter worth approximately $26,000. 73.71% of the stock is owned by institutional investors and hedge funds.
About Geron
(
Get Free Report)
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.
Featured Articles
Before you consider Geron, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Geron wasn't on the list.
While Geron currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.
Get This Free Report
